Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ECL stock price vs MRNA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRNA's multiple
Needs MRNA P/E.
Implied fair value · at ECL's multiple
Needs Annual EPS is negative, ECL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ECOLAB INC. · implied price per share
Bear
$44.93
Base
$57.49
Bull
$73.86
Moderna, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Procter & Gamble Company
ECL vs PG
COLGATE PALMOLIVE CO
ECL vs CL
CLOROX CO /DE/
ECL vs CLX
KIMBERLY CLARK CORP
ECL vs KMB
PFIZER INC
ECL vs PFE
JOHNSON & JOHNSON
ECL vs JNJ
GILEAD SCIENCES, INC.
ECL vs GILD
AMGEN INC
ECL vs AMGN
NOVAVAX INC
ECL vs NVAX
VERTEX PHARMACEUTICALS INC / MA
ECL vs VRTX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ECL’s stable profitability and modest growth deserve a higher multiple than the current market price, then ECL looks attractive on a relative basis because it is profitable, growing, and still trades below MRNA-implied valuation.
MRNA-based valuation framework implies $642.08 for ECL versus a current price of $277.63, suggesting 131.3% upside and a large apparent discount to MRNA multiple. That gap is driven primarily by ECL’s much stronger profitability and steadier growth profile compared with MRNA’s deeply negative earnings and contracting revenue.
Supporting Metrics
